NO992296L - FremgangsmÕte for disubstituerte pyridiner - Google Patents

FremgangsmÕte for disubstituerte pyridiner

Info

Publication number
NO992296L
NO992296L NO992296A NO992296A NO992296L NO 992296 L NO992296 L NO 992296L NO 992296 A NO992296 A NO 992296A NO 992296 A NO992296 A NO 992296A NO 992296 L NO992296 L NO 992296L
Authority
NO
Norway
Prior art keywords
formula
amino
nitro
processes
preparation
Prior art date
Application number
NO992296A
Other languages
English (en)
Other versions
NO992296D0 (no
Inventor
Keith Michael Devries
Robert Lee Dow
Stephen Wayne Wright
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of NO992296D0 publication Critical patent/NO992296D0/no
Publication of NO992296L publication Critical patent/NO992296L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Denne oppfinnelse vedrører fremgangsmåter for fremstilling av forbindelser med formel (l) som er p-adrenerge reseptoragonister, og fremgangsmåter for frem- stilling av visse mellomprodukter med formel (IIA) hvori R1 er nitro, amino eller beskyttet amino; R2 er H, fluor, klor, CF3, nitro, (d-C4)alkyl, (Ci-C4)alkoksy, amino eller beskyttet amino; og X1 er OH eller en egnet utgående gruppe, anvendt i denne fremgangsmåte. Oppfinnelsen angår også nye forbindelser med formelen (II).
NO992296A 1996-11-14 1999-05-12 FremgangsmÕte for disubstituerte pyridiner NO992296L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3088096P 1996-11-14 1996-11-14
PCT/IB1997/001367 WO1998021184A1 (en) 1996-11-14 1997-11-03 Process for substituted pyridines

Publications (2)

Publication Number Publication Date
NO992296D0 NO992296D0 (no) 1999-05-12
NO992296L true NO992296L (no) 1999-05-12

Family

ID=21856496

Family Applications (1)

Application Number Title Priority Date Filing Date
NO992296A NO992296L (no) 1996-11-14 1999-05-12 FremgangsmÕte for disubstituerte pyridiner

Country Status (32)

Country Link
US (1) US6291489B1 (no)
EP (1) EP0938476B1 (no)
JP (1) JP3510635B2 (no)
KR (1) KR20000053314A (no)
CN (1) CN1237160A (no)
AP (1) AP805A (no)
AR (1) AR010584A1 (no)
AT (1) ATE319687T1 (no)
AU (1) AU4634697A (no)
BG (1) BG103393A (no)
BR (1) BR9712951A (no)
CA (1) CA2270386C (no)
CO (1) CO4930261A1 (no)
DE (1) DE69735433D1 (no)
EA (1) EA199900375A1 (no)
GT (1) GT199700118A (no)
HR (1) HRP970612A2 (no)
ID (1) ID18898A (no)
IL (1) IL129688A0 (no)
IS (1) IS5029A (no)
MA (1) MA24401A1 (no)
MY (1) MY132507A (no)
NO (1) NO992296L (no)
OA (1) OA11044A (no)
PA (1) PA8441401A1 (no)
PE (1) PE10299A1 (no)
TN (1) TNSN97172A1 (no)
TR (1) TR199901063T2 (no)
UY (1) UY24774A1 (no)
WO (1) WO1998021184A1 (no)
YU (1) YU22099A (no)
ZA (1) ZA9710186B (no)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010042518A (ko) * 1998-04-08 2001-05-25 한스 루돌프 하우스, 헨리테 브룬너, 베아트리체 귄터 신규 제초제
US6090942A (en) * 1998-10-15 2000-07-18 Pfizer Inc. Process and intermediates for a β3 -adrenergic receptor agonist
HUP0200092A3 (en) 1999-02-16 2003-02-28 Kaneka Corp Substituted acetylpyridine derivatives and process for the preparation of intermediates for optically active betha-3 agonist by the use of the same
US6455734B1 (en) * 2000-08-09 2002-09-24 Magnesium Diagnostics, Inc. Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states
EP1078924B1 (en) * 1999-07-23 2004-10-20 Pfizer Products Inc. Intermediates and a process for producing beta-adrenergic receptor agonists
WO2003033468A1 (en) * 2001-10-17 2003-04-24 Kaneka Corporation PROCESS FOR PREPARATION OF (S)-α-HALOMETHYLPYRIDINE- METHANOL DERIVATIVES
WO2003072573A1 (en) * 2002-02-27 2003-09-04 Pfizer Products Inc. Crystal forms of (r)-2-(2-(4-oxazol-4-yl-phenoxy)-ethylamino)-1-pyridin-3-yl-ethanol
JP2005520501A (ja) 2002-02-27 2005-07-14 ファイザー・プロダクツ・インク β３−アドレナリン作用性レセプターアゴニストを製造するのに有用な方法及び中間体
US6864268B2 (en) 2002-02-27 2005-03-08 Pfizer Inc. β3 adrenergic receptor agonists
EP1424079A1 (en) * 2002-11-27 2004-06-02 Boehringer Ingelheim International GmbH Combination of a beta-3-receptor agonist and of a reuptake inhibitor of serotonin and/or norepinephrine
KR100751163B1 (ko) 2003-05-09 2007-08-22 에프. 호프만-라 로슈 아게 알파-1 아드레날린 작용물질로서의 메틸 인돌 및 메틸피롤로피리딘
US7977359B2 (en) 2005-11-04 2011-07-12 Amira Pharmaceuticals, Inc. 5-lipdxygenase-activating protein (FLAP) inhibitors
GB2431927B (en) 2005-11-04 2010-03-17 Amira Pharmaceuticals Inc 5-Lipoxygenase-activating protein (FLAP) inhibitors
US8399666B2 (en) 2005-11-04 2013-03-19 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors
JP5791500B2 (ja) 2008-05-23 2015-10-07 パンミラ ファーマシューティカルズ，エルエルシー． ５−リポキシゲナーゼ活性化タンパク質阻害剤
US8546431B2 (en) 2008-10-01 2013-10-01 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4358455A (en) 1980-12-23 1982-11-09 Merck & Co., Inc. Aralkylamindethanol heterocyclic compounds
US5019578A (en) 1987-11-27 1991-05-28 Merck & Co., Inc. β-adrenergic agonists
BR9406823A (pt) 1993-06-14 1996-03-26 Pfizer Aminas secundárias e agentes anti-diabéticos e antiobesidade
IL113410A (en) 1994-04-26 1999-11-30 Merck & Co Inc Substituted sulfonamides having an asymmetric center and pharmaceutical compositions containing them
CA2220399A1 (en) 1995-05-10 1996-11-14 Pfizer Inc. .beta.-adrenergic agonists
EP0828712A1 (en) 1995-05-10 1998-03-18 Pfizer Inc. Beta-adrenergic agonists

Also Published As

Publication number Publication date
US6291489B1 (en) 2001-09-18
PE10299A1 (es) 1999-02-10
CN1237160A (zh) 1999-12-01
CA2270386C (en) 2004-08-03
WO1998021184A1 (en) 1998-05-22
MA24401A1 (fr) 1998-07-01
AR010584A1 (es) 2000-06-28
JP2000504347A (ja) 2000-04-11
ATE319687T1 (de) 2006-03-15
YU22099A (sh) 2001-09-28
AU4634697A (en) 1998-06-03
EP0938476B1 (en) 2006-03-08
ID18898A (id) 1998-05-20
IL129688A0 (en) 2000-02-29
CO4930261A1 (es) 2000-06-27
ZA9710186B (en) 1999-05-12
UY24774A1 (es) 1998-05-05
CA2270386A1 (en) 1998-05-22
OA11044A (en) 2002-02-20
NO992296D0 (no) 1999-05-12
BG103393A (en) 2000-07-31
BR9712951A (pt) 1999-12-07
KR20000053314A (ko) 2000-08-25
DE69735433D1 (de) 2006-05-04
GT199700118A (es) 1999-05-05
AP9701147A0 (en) 1998-01-31
EP0938476A1 (en) 1999-09-01
TR199901063T2 (xx) 1999-08-23
HRP970612A2 (en) 1998-08-31
TNSN97172A1 (fr) 2005-03-15
JP3510635B2 (ja) 2004-03-29
IS5029A (is) 1999-04-16
MY132507A (en) 2007-10-31
AP805A (en) 2000-01-28
PA8441401A1 (es) 2000-05-24
EA199900375A1 (ru) 1999-12-29

Similar Documents

Publication Publication Date Title
NO992296L (no) FremgangsmÕte for disubstituerte pyridiner
Yasuhara et al. Selective monodesulfonylation of N, N-disulfonylarylamines with tetrabutylammonium fluoride
ATE269312T1 (de) N-(amidinophenyl)-n'-(subst.)-3h-2,4- benzodiazepin-3-on derivative als faktor xa inhibitoren
NO955047L (no) Sekundære aminer som antidiabetiske og antifedme-midler
YU34896A (sh) Supstituisani n-(indol-2-karbonil)-glicinamidi, njihovi intermedijeri i farmaceutske kompozicije
ATE185558T1 (de) Prostaglandin-synthase hemmer
DK0380063T3 (da) 1,2-Cyclohexylaminoarylamider til anvendelse som analgetika
DK0715628T3 (da) Substituerede azaindolyliden-forbindelser og fremgangsmåde til fremstilling deraf
BR9509665A (pt) Composto composições e métodos
PT923554E (pt) N-benzilpiperidina e derivados tetrahidropiridina
DE69433984D1 (de) Arylpiperazinderivate von indol als liganden der rezeptoren 5 ht1-like, 5 ht1b und 5 ht1d
BR9508608A (pt) Composto formulação farmacêutica e processo para prevenir ou tratar arritmia
NO985335L (no) 2,4-Diaminopyrimidinderivater
NO952205L (no) Heterocykliske karbamater, fremgangsmåte for fremstilling derav og medikamenter
NO924988D0 (no) Tiazolidinforbindelser som inneholder kinongrupper, og fremgangsmaate til fremstilling derav
DK0601486T3 (da) Cis-epoxidderivater, der er egnede som irreversible HIV-proteaseinhibitorer, og fremgangsmåde og mellemprodukter til deres
DK1404642T3 (da) Fremgangsmåde til fremstillimg af 7-amino-syn-3,5-dihydroxyheptansyrederivater, mellemprodukter derfor og fremgangsmåder til deres fremstilling
DK362584D0 (da) 1-substituerede 4-hydroxymethylpyrrolidinoner, fremgangsmaade til fremstilling deraf, farmaceutiske praeparater og mellemprodukter
NO20041573L (no) Aralkyl-tetrahydro-pyridiner, deres fremstilling og farmasoytiske preparater inneholdende de samme
SE8501988L (sv) Iminotiazolidinderivat
DK0552758T3 (da) N-5-Beskyttede 2,5-diamino-4,6-dichlorpyrimidiner og fremgangsmåde til deres fremstilling
EA200401099A1 (ru) Производные гетероциклического амида
TR199800957T2 (xx) Dioksoazabisikloheksanlar haz�rlama i�lemi.
ATE162191T1 (de) Azanoradamantane
AR003964A1 (es) Nuevos azepanos y homologos de su anillo, compuestos de partida para su preparacion, procedimiento para la elaboracion de dichos azepanos y sushomologos de anillo y composiciones farmaceuticas que los contienen.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application